Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarker-guided Precision Treatment in First-line Advanced Esophageal Squamous Cell Carcinoma
NCT07709533Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jul 2026
- Primary completion
- Jun 2029
- Countries
- 1
01
Overview
A Phase 2 trial of retlirafusp alfa, indole-3-carbinol, lactobacillus rhamnosus in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Sun Yat-sen University. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
retlirafusp alfaindole-3-carbinollactobacillus rhamnosus
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT07709533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07709533.